Table 3.
Associations between IL-6 promoter methylation levels and clinicopathological features in HCC.
| Parameters | Total number | PMR (%) | P value |
|---|---|---|---|
| Gender | 0.028a* | ||
| Male | 106 | 53.70 (52.03-55.00) | |
| Female | 27 | 52.72 (51.07-54.16) | |
| Age (year) | 0.040a* | ||
| <=50 | 28 | 52.54 (51.23-54.57) | |
| >50 | 105 | 53.73 (52.33-54.82) | |
| HBeAg | 0.314a | ||
| Negative | 70 | 53.18 (51.74-54.61) | |
| Positive | 63 | 53.96 (52.33-55.41) | |
| HBV-DNA | 0. 044a* | ||
| Negative | 63 | 53.67 (52.40-55.85) | |
| Positive | 70 | 53.24 (51.53-54.58) | |
| AFP (ng/ml) | 0.532a | ||
| <=20 | 53 | 53.41 (52.03-54.60) | |
| >20 | 80 | 53.68 (51.82-55.25) | |
| Primary tumor number | 0.801a | ||
| single | 94 | 53.58 (52.02-54.75) | |
| multiple | 39 | 53.62 (51.34-54.91) | |
| Tumor size | 0.032a* | ||
| <=3 cm | 73 | 53.42 (52.01-54.43) | |
| >3 cm | 60 | 53.81 (51.85-55.97) | |
| Vascular invasion | 0.658a | ||
| Negative | 73 | 53.83 (52.15-54.70) | |
| Positive | 60 | 53.13 (51.97-54.84) | |
| CTP staging | 0.308b | ||
| A | 61 | 53.72 (51.87-55.06) | |
| B | 36 | 53.52 (52.48-54.75) | |
| C | 36 | 54.40 (52.00-54.67) | |
| BCLC staging | 0.389a | ||
| 0/1/2 | 83 | 53.63 (52.02-54.76) | |
| 3/4 | 50 | 53.50 (51.72-54.77) | |
| Ascites | 0.212a | ||
| No | 86 | 8.12 (4.50-20.97) | |
| Yes | 47 | 6.95 (1.88-22.31) | |
| Encephalopathy | 0.082a | ||
| No | 124 | 7.58 (2.72-18.92) | |
| Yes | 9 | 4.77 (2.99-9.41) |
CTP, Child–Turcotte–Pugh; BCLC, Barcelona-Clinical-Liver-Cancer.
*p<0.05.
**p<0.01.
***p<0.001.
aann–Whitney U test.
bKruskal–Wallis H test.